Real world outcomes of novel targeted agents for the treatment of metastatic HER-2 positive breast cancer in Ontario: A population-based study
Real world outcomes of novel targeted agents for the treatment of metastatic HER-2 positive breast cancer in Ontario: A population-based study
安大略省用于治疗转移性 HER-2 阳性乳腺癌的新型靶向药物的真实世界结果：一项基于人群的研究
批准号：
391524
负责人：
Ethier Josee-Lyne
金额：
$7.14万
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-10-01 至 2019-10-01
中文摘要
翻译
直到最近，被诊断患有一种HER2受体呈阳性并已扩散到身体其他部位的乳腺癌的妇女，最初接受化疗和一种名为曲妥珠单抗的抗体治疗。如果他们的癌症继续发展
英文摘要
Until recently, women diagnosed with a type of breast cancer which is positive for the HER2 receptor and has spread to other parts of their body were initially treated with chemotherapy and an antibody called trastuzumab. If their cancer progressed despit
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Real-World Outcomes Associated with PARP Inhibitor Maintenance Therapy in Ovarian Cancer: A Population-Based Study
-
批准号：472669
-
项目类别：Operating Grants
-
资助金额：$7.29万
-
财政年份：2022
-
负责人：Ethier Josee-Lyne
-
依托单位：
海外基金
